eCite Digital Repository

Lymphoma studies by the Australasian Leukaemia and Lymphoma Group


Lowenthal, RM and Stone, JM, Lymphoma studies by the Australasian Leukaemia and Lymphoma Group, Transfusion and Apheresis Science, 49, (2) pp. 110-112. ISSN 1473-0502 (2013) [Contribution to Refereed Journal]

DOI: doi:10.1016/j.transci.2013.07.010


The Australasian Leukaemia and Lymphoma Group (ALLG) can trace its origins to 1973. It now encompasses virtually all the major hospitals in Australia and New Zealand that treat leukaemias and lymphomas. Over the years the Group as a whole, and members individually, have participated in many clinical treatment trials for aggressive lymphomas. Initially trials were conceived and carried out locally, but in recent years, in addition to continuing its own studies, the Group has been a major contributor to international trials including two that have been particularly influential, known as MInT and CORAL. The MInT study confirmed the value of adding rituximab to standard chemotherapy for aggressive lymphomas; CORAL helped define optimum methods of autografting for relapse. The ALLG has contributed and continues to contribute to the improving outcome for patients with aggressive lymphomas.

Item Details

Item Type:Contribution to Refereed Journal
Research Division:Biomedical and Clinical Sciences
Research Group:Cardiovascular medicine and haematology
Research Field:Haematology
Objective Division:Health
Objective Group:Clinical health
Objective Field:Clinical health not elsewhere classified
UTAS Author:Lowenthal, RM (Professor Ray Lowenthal)
ID Code:89977
Year Published:2013
Deposited By:Menzies Institute for Medical Research
Deposited On:2014-03-20
Last Modified:2014-03-20

Repository Staff Only: item control page